Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC. Issue 9 (23rd May 2016)

• Record Type: Journal Article
• Authors: Starr, Amanda E; Deeke, Shelley A; Ning, Zhibin; Chiang, Cheng-Kang; Zhang, Xu; Mottawea, Walid; Singleton, Ruth; Benchimol, Eric I; Wen, Ming; Mack, David R; Stintzi, Alain; Figeys, Daniel
• Is Part Of: Gut. Volume 66:Issue 9(2017)
• Page Start: 1573
• Page End: 1583
• Publication Date: 2016-05-23
• Subjects: IBD -- CROHN'S DISEASE -- ULCERATIVE COLITIS -- IBD BASIC RESEARCH; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2015-310705
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Accurate differentiation between Crohn's disease (CD) and UC is important to ensure early and appropriate therapeutic intervention. We sought to identify proteins that enable differentiation between CD and UC in children with new onset IBD. Design: Mucosal biopsies were obtained from children undergoing baseline diagnostic endoscopy prior to therapeutic interventions. Using a super-stable isotope labeling with amino acids in cell culture (SILAC)-based approach, the proteomes of 99 paediatric control and biopsies of patients with CD and UC were compared. Multivariate analysis of a subset of these (n=50) was applied to identify novel biomarkers, which were validated in a second subset (n=49). Results: In the discovery cohort, a panel of five proteins was sufficient to distinguish control from IBD-affected tissue biopsies with an AUC of 1.0 (95% CI 0.99 to 1.0); a second panel of 12 proteins segregated inflamed CD from UC within an AUC of 0.95 (95% CI 0.86 to 1.0). Application of the two panels to the validation cohort resulted in accurate classification of 95.9% (IBD from control) and 80% (CD from UC) of patients. 116 proteins were identified to have correlation with the severity of disease, four of which were components of the two panels, including visfatin and metallothionein-2. Conclusions: This study has identified two panels of candidate biomarkers for the diagnosis of IBD and the differentiation of IBD subtypes to guide appropriate therapeutic interventions in paediatric patients.